ArticleScientific reports2025
Exploring the novel paper wasp (Parapolybia escalerae) honey for green synthesis of silver nanoparticles with antibacterial properties.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mild-condition green synthesis of manganese nanoparticles for next-generation broad-spectrum antibacterial applications.RSC advances · 2026Article
- Bioengineered Ag/AgCl nanoparticles fromNanoscale advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of green-based nanomaterials as antimicrobial agents offers a sustainable and safe alternative to conventional antibiotics, aligning with both environmental and public health priorities. The paper wasp (Parapolybia escalerae) is a novel species known for its unique honey, which has not been previously explored for its potential in green nanotechnology and biomedical applications. In this study, paper wasp honey was used to prepare silver nanoparticles (H-Ag NPs), which serves a dual role as both the reducing and stabilizing agent. The structural, morphological, and optical characteristics of the biosynthesized nanoparticles were assessed using UV-Vis double beam spectroscopy, X-ray diffraction (XRD) pattern, Fourier transform infrared (FTIR) spectroscopy, and scanning electron microscopy (SEM). Additionally, the antibacterial potential of the synthesized H-Ag NPs was evaluated against gram-positive bacteria Staphylococcus aureus (ATCC 6538), Staphylococcus aureus MRSA, and multidrug-resistant gram-negative bacteria Acinetobacter baumannii by determining their minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) using the broth microdilution method. Notably, MIC and MBC of this nanoparticle against S. aureus (ATCC 6538) and S. aureus MRSA strains were found to be 17.5 µg/mL. Additionally, at lesser doses (8.5 µg/mL), these nanoparticles can inhibit the growth of the Gram-negative bacteria A. baumannii. The novel feature of this method lies in its environmentally friendly and sustainable approach, as it avoids the use of hazardous chemicals typically employed in conventional synthesis methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.